Navigation Links
diaDexus, Inc. Reports 2011 Fourth Quarter and Year-End Financial Results
Date:3/16/2012

its guidance for 2012 total revenues at $20 million to $21 million, projecting year-over-year growth of approximately 26% compared to 2011.  The company believes it will use approximately $6 million in operations. Future financing needs will depend on the company's ability to increase the rate of adoption for the company's products by physicians, progress in achieving additional positive coverage decisions from insurers for the PLAC® Test for Lp-PLA(2), and commercialization needs.

"diaDexus had an outstanding fiscal 2011, the strongest fourth quarter in the history of the company, and grew revenues to a record of $16.4 million," said Brian Ward, Ph.D., diaDexus' Chief Executive Officer. "We are gaining strong momentum with acceptance of the PLAC Lp-PLA(2) Mass testing as an essential biomarker that aids physicians by indicating the risk of cardiovascular heart disease and stroke in the United States. With the launch of diaDexus' new PLAC® Test for Lp-PLA(2) Activity in Europe in the first quarter of 2012, we are now positioned for further long-term sales momentum.  The recent hire of Jean Viret as our Chief Financial Officer completes our executive management team, and allows us to maintain our sales momentum and deliver increased value to our shareholders."

Webcast

diaDexus will host a webcast on Thursday, March 15 at 1:15 PM PDT (4:15 PM EDT) to discuss the 2011 fourth quarter and year-end financial results. The webcast may be accessed via the company's website at www.diadexus.com/webcast.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of proprietary in vitro diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test for Lp-PLA(2) is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and i
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
2. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
3. diaDexus, Inc. Reports 2011 First Quarter Financial Results
4. diaDexus, Inc. Reports 38% Year-Over-Year Revenue Growth for 2011 Third Quarter
5. diaDexus, Inc. to Host Webcast March 15, 2012 on 2011 Fourth Quarter and Year-End Financial Results
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  Armada Health ... of the new Armada corporate website ( www.armadahealthcare.com ... communicate Armada,s unique and first-to-market services and its ... focused on the specialty pharmacy industry. ... of the Armada business model in delivering an ...
(Date:5/21/2013)... May 21, 2013 Hurel Corporation ("Hurel"), a ... cell-based assay platforms, today announced the appointment of ... the Company,s Board of Directors. Dr. MacDonald is the ... Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development ... Merck & Co. in 2009. Over a ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
... EORTC 40983 (EPOC),Intergroup Study Results, CHICAGO, June ... phase III EORTC 40983 Intergroup study, or ... peri-operative (pre and post,surgery) FOLFOX4 (Eloxatin(R) (oxaliplatin ... for colon cancer,5-fluorouracil/leucovorin (5-FU/LV)) given to patients ...
... Phase II Study Results Presented at Society ... 04, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... with the radioisotope,iodine-131, was found to be ...
Cached Medicine Technology:The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
(Date:5/21/2013)... (PRWEB) May 21, 2013 HealthSmart continues ... expanding national presence has required the hiring of new ... HealthSmart is pleased to announce that Dawn Powell has ... serving as the Director of Account Management in the ... offices in Irving, Texas. With extensive client management, employee ...
(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...
(Date:5/21/2013)... Phoseon Technology will present their advanced ... Annual IMI European Ink Jet Conference (June 5-6, ... continues to invest in product development to enable breakthrough ... LED curing in printing applications. Phoseon currently has ... offering both air cooled and water cooled solutions to ...
(Date:5/21/2013)... Modern couples have countless strains on ... Sexuality and Relationship Workshops, couples are learning the ... habits for their relationship. There are both private ... individuals at Texas Counseling. Their goal is to ... to develop long term solutions. , Developing ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
Breaking Medicine News(10 mins):Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2
... CORVALLIS, Ore. Researchers have developed a type of wearable, ... heart rate and respiration at the same time it records ... diagnostics and patient care. The device is just two ... contact with the skin and can operate for a week ...
... magnetic resonance equipment available, researchers at the University of ... structure of biological molecules -- potentially leading to new ... cancer and Alzheimer,s disease. The findings appear in ... and Journal of Biological Chemistry "These ...
... -- About one million packets of birth control pills are ... of a packaging error that could reduce the effectiveness of ... 14 lots of Lo/Ovral-28 tablets and 14 lots of generic ... Pfizer discovered that some blister packs may contain either too ...
... Kathleen Doheny HealthDay Reporter , WEDNESDAY, Feb. 1 ... pauses in breathing during sleep, is already known to boost ... apnea to so-called silent strokes, in which there is tissue ... study, researchers found that rapid memory loss before a stroke ...
... (HealthDay News) -- Many adults whose parents suffered a stroke ... middle age that may precede a stroke, a new study ... age of 61 who underwent MRI brain scans to assess ... white matter lesions and other signs of aging or damage ...
... multiforme (GBM) is the most common of all malignant ... GBM have a poor prognosis because it is a ... to current therapies. New therapeutic approaches are therefore much ... University of California, San Francisco, have now identified a ...
Cached Medicine News:Health News:Protein structures give disease clues 2Health News:Pfizer Recalls 1 Million Packets of Birth Control Pills 2Health News:Sleep Apnea May Be Tied to 'Silent' Strokes, Study Finds 2Health News:Sleep Apnea May Be Tied to 'Silent' Strokes, Study Finds 3Health News:Adult Children of Stroke Sufferers May Show Signs of Brain Aging, Too 2
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
... offers a display, ramp capabilities ... also has features that make ... session meter records the number ... than four hours - giving ...
... CPAP System is the smallest and lightest ... the market. It is designed to help ... while complying with therapy. The GoodKnight 420S ... date/time usage data. It also detects persistent ...
Micro-hematocrit tubes available in multiple sizes and additives for a wide range of capillary blood collection....
Medicine Products: